Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant Recipients

Sotrastaurin, a novel protein‐kinase‐C inhibitor, blocks early T‐cell activation. In this 12‐month, Phase II study, de novo renal‐transplant patients were randomized to sotrastaurin (200 mg b.i.d.) + standard‐exposure tacrolimus (SET) or reduced‐exposure tacrolimus (RET) (SET: n = 76; RET: n = 66),...

Ausführliche Beschreibung